Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT 9 open-label ibandronate loading-dose study in NSCLC with painful bone metastases
NL-OMON19953Phase 2Active, not recruiting
- Sponsor
- NVALT Oncology
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibandronic acid in non-small cell lung cancer (NSCLC) and bone metastases, sponsored by NVALT Oncology. Primary endpoint: Bone pain response over 7 days. Started Dec 2007; status: active, not recruiting.
02
Drugs
ibandronic acid
03
Conditions
non-small cell lung cancer (NSCLC)bone metastases
Beyond the preview
Go deeper on NL-OMON19953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19953.